Molecular Advances in Diffuse Large B-Cell Lymphoma
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Molecular Cancer Biology".
Deadline for manuscript submissions: closed (31 December 2021) | Viewed by 24959
Special Issue Editors
Interests: lymphoma; prognosis; molecular background
Special Issues, Collections and Topics in MDPI journals
Interests: surgical pathology and hematopathology; molecular pathology; clinical research; translational cancer research; targeted therapeutics; new molecular assays and technologies; personalized medicine
Interests: EBV-positive DLBCL lymphomas; plasmablastic lymphomas
Special Issues, Collections and Topics in MDPI journals
Interests: extranodal DLBCL; DLBCL in children
Special Issue Information
Dear Colleagues,
Diffuse large B-cell lymphomas are heterogeneous aggressive lymphomas whose molecular background is still poorly understood. They are biologically and clinically different based on age (children, adults, elderly) of onset, place of development (nodal vs. extranodal), viral relationship, and immunosurveillance. Moreover, genetic subgroups have also been identified, such as high grade B-cell lymphomas with double or triple MYC/BCL2/BCL6 gene rearrangements, 11q Burkitt-like lymphoma, IRF4 translocated, or ALK translocated lymphomas, among others. We are proposing an extended review of new molecular advances in diffuse large B-cell lymphomas, taking into account all these previous features. Moreover, we highlight the existence of new approaches for high-grade B-cell lymphoma identification.
Prof. Dr. Socorro María Rodríguez-Pinilla
Dr. Arantza Onaindia
Dr. Paola A Chabay
Dr. Fina Climent
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- DLBCL
- genetics
- molecular
- Epstein–Barr virus
- immunodeficiency
- IRF4
- ALK
- high-grade B-cell lymphomas
- extranodal DLBCL
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue policies can be found here.